Welch Allyn, Masimo integrate

Health IT companies Welch Allyn and Masimo have agreed on an integration strategy that will make the Masimo rainbow SET Pulse CO-Oximetry technology platform an offering in Welch Allyn's new product line.

This strategy will provide clinicians with a host of noninvasive, continuous measurements and patient monitoring capabilities, and will allow clinicians to add the Irvine, Calif.-based Masimo's measurements as optional software upgrades as the measurements become commercially available for use with the Welch Allyn patient monitor.

Masimo rainbow SET measurements provide physiological data that helps clinicians assess patients and detect adverse conditions. Pending regulatory clearance, Welch Allyn will announce the commercial availability of these rainbow SET parameters as they become legally available for use with its monitors, the Skaneateles Falls, N.Y.-based Welch Allyn stated.

The new Welch Allyn Connex Vital Signs Monitor (CVSM) is the first Welch Allyn monitor to integrate the Masimo rainbow SET technology. The CVSM incorporates Masimo's SpO2-enabled measurements and is capable of being field upgraded to add rainbow SET-based measurements as each parameter becomes commercially available for use with the CVSM, the companies added.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.